[{"orgOrder":0,"company":"FSD Pharma","sponsor":"Solarvest BioEnergy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FSD Pharma and Solarvest Enhance Commitment to CBD Research Project","therapeuticArea":"Neurology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Undisclosed"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Receives U.S. FDA Approval to Design a Phase 2a Clinical Trial To Treat Patients With Suspected or Confirmed Covid-19 Diagnosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients With COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Announces First Patient Randomized in Phase 2 Trial of FSD201 for the Treatment of Hospitalized Patients with COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Lucid Psycheceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Lucid Psycheceuticals","pharmaFlowCategory":"D","amount":"$8.9 million","upfrontCash":"Undisclosed","newsHeadline":"FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Covar Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FSD Pharma Signs Agreement with Covar Pharmaceuticals to Support the Development of Lucid-PSYCH","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Files Investigational New Drug Application (\u201cIND\u201d) with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Lucid Psycheceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Submits Its Phase-1 Clinical Trial Application for Lucid-Ms (lucid-21-302) for First-In-Human Safety and Tolerability Investigation","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recruiting Underway in FSD Pharma\u2019s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"FSD Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by FSD Pharma
The agreement aims to evaluate the safety and pharmacokinetics of Lucid-21-302, a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis.
Lucid-MS (lucid-21-302) is a first-in-class neuroprotective compound with a novel mechanism of action which, in preclinical models, has shown to prevent myelin degradation (demyelination), a cause for MS and other neurodegenerative diseases.
Lucid-MS (lucid-21-302) is a patented first-in-class, small molecule inhibitor of hypercitrullination, New Chemical Entity and a neuroprotective compound with a novel mechanism of action for the treatment of Multiple Sclerosis.
Lucid-MS (lucid-21-302) is a first-in-class neuroprotective compound with a novel mechanism action which, in preclinical models, has shown to prevent myelin degradation (demyelination), a cause for MS and other neurodegenerative diseases.
Lucid-201 is a psychedelic drug candidate targeting mental health disorders, and it is also investigating certain cannabinoids. FSD Pharma has established an Australian subsidiary to facilitate its development of Lucid-Psych and potentially other assets.
Substance misuse is one of the most pervasive challenges around the globe, keeping this it in mind, company has announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse disorder.
Lucid-MS (lucid-21-302) is a first-in-class neuroprotective compound with a novel mechanism action which, in preclinical models, has shown to prevent myelin degradation (demyelination), a cause for MS and other neurodegenerative diseases.
FSD201 (palmitoylethanolamide) with enhanced anti-inflammatory properties, it is a fatty acid amide currently used as a dietary supplement, by increasing its bioavailability and efficacy making it suitable to treat a range of inflammatory conditions
Lucid-MS (lucid-21-302) is a first-in-class neuroprotective compound with a novel mechanism action which, in preclinical models, has shown to prevent myelin degradation (demyelination), a cause for MS and other neurodegenerative diseases.
Lucid-201 is a psychedelic drug candidate targeting mental health disorders, and it is also investigating certain cannabinoids. FSD Pharma has established an Australian subsidiary to facilitate its development of Lucid-Psych and potentially other assets.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
